伊布替尼
套细胞淋巴瘤
布鲁顿酪氨酸激酶
癌症研究
癸他滨
胞苷脱氨酶
淋巴瘤
细胞生物学
酪氨酸激酶
生物
DNA甲基化
信号转导
免疫学
白血病
生物化学
基因表达
基因
慢性淋巴细胞白血病
作者
Nguyet-Minh Hoang,Yunxia Liu,Paul D. Bates,Alexa R. Heaton,Angelica F. Lopez,Peng Liu,Fen Zhu,Ruoyu Chen,Apoorv Kondapelli,Xiyu Zhang,Paul E. Selberg,Vu N. Ngo,Melissa C. Skala,Christian M. Capitini,Lixin Rui
标识
DOI:10.1016/j.xcrm.2024.101484
摘要
The use of Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib achieves a remarkable clinical response in mantle cell lymphoma (MCL). Acquired drug resistance, however, is significant and affects long-term survival of MCL patients. Here, we demonstrate that DNA methyltransferase 3A (DNMT3A) is involved in ibrutinib resistance. We find that DNMT3A expression is upregulated upon ibrutinib treatment in ibrutinib-resistant MCL cells. Genetic and pharmacological analyses reveal that DNMT3A mediates ibrutinib resistance independent of its DNA-methylation function. Mechanistically, DNMT3A induces the expression of MYC target genes through interaction with the transcription factors MEF2B and MYC, thus mediating metabolic reprogramming to oxidative phosphorylation (OXPHOS). Targeting DNMT3A with low-dose decitabine inhibits the growth of ibrutinib-resistant lymphoma cells both in vitro and in a patient-derived xenograft mouse model. These findings suggest that targeting DNMT3A-mediated metabolic reprogramming to OXPHOS with decitabine provides a potential therapeutic strategy to overcome ibrutinib resistance in relapsed/refractory MCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI